Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal Antibody

Treatment with IDEC‐C2B8 (C2B8), the chimeric anti‐CD20 antibody, was shown in a phase I‐II study to be very effective for the treatment of low‐grade B‐cell lymphoma, in contrast to the results of most previous immunotherapies with monoclonal antibodies. In a study designed to elucidate the reason f...

Descripción completa

Detalles Bibliográficos
Autores principales: Taji, Hirohumi, Kagami, Yoshitoyo, Okada, Yasutaka, Andou, Manabu, Nishi, Yoshimi, Saito, Hidehiko, Seto, Masao, Morishima, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1998
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921892/
https://www.ncbi.nlm.nih.gov/pubmed/9738982
http://dx.doi.org/10.1111/j.1349-7006.1998.tb03280.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921892/
https://www.ncbi.nlm.nih.gov/pubmed/9738982
http://dx.doi.org/10.1111/j.1349-7006.1998.tb03280.x

Ejemplares similares